ONO-7913
Atopic dermatitis
Phase 2Active
Key Facts
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd. is one of Japan's oldest and most established pharmaceutical companies with over 300 years of history. The company has evolved from traditional medicine to become a leader in oncology, particularly through its co-development of Opdivo with Bristol Myers Squibb, which has become one of the world's leading cancer immunotherapies. Ono maintains a strong focus on research and development with particular expertise in immunology, oncology, and CNS disorders, while expanding its presence in international markets.
View full company profileTherapeutic Areas
Other Atopic dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Phase 3 |
| Dupixent | Sanofi | Commercial |
| ASP2408 | Astellas Pharma | Phase 2 |
| KW-6356 | Kyowa Kirin | Phase 2 |
| KHK4083 | Kyowa Kirin | Phase 2 |
| Opzelura (ruxolitinib cream) | Ono Pharmaceutical | Approved |
| KT-474 | Kymera Therapeutics | Phase 2 |
| GRC 27864 | Glenmark Pharmaceuticals | Phase 2 |
| ARQ-234 | Arcutis Biotherapeutics | Preclinical/Phase 1 |
| STAR-0310 | BioCryst Pharmaceuticals | Phase 1 |
| Rezpegaldesleukin | Nektar Therapeutics | Phase 2b |
| ZL-1503 | Zai Lab | Phase (Early Clinical) |